-
CaMKII as a Therapeutic Target in Parkinson's Disease
… We anticipate that such interventions will help manage dyskinesias and other debilitating side effects associated … levodopa-based therapies. … Complications of Treatment … Dyskinesia … Tennessee … United States … Academia/Nonprofit …
-
Pathway Validation of a Biased Delta Opioid Receptor Ligand for PD Symptoms & Side Effects Relief
… of this class of molecule for therapeutic utility in PD. … Dyskinesia … Clinical Trial … Ontario … Canada … Target …
-
Dry Powder-Based Delivery of Intrapulmonary Levodopa as a Treatment for Motor Fluctuations in Parkinson's Disease
… to the development of both motor fluctuations and dyskinesias. As an adjunct to standard oral therapies, … in motor function was also demonstrated with no increase in dyskinesia relative to oral levodopa administration. … Announces MJFF Grant … Symptoms & Side Effects … Dyskinesia … Therapeutic Development … Massachusetts … …
-
LRRK2 Physiology in Parkinson's Disease
… between Parkinson’s patients and control subjects. … Dyskinesia … Clinical Trial … Illinois … United States … …
-
Development of Hsf1 Effectors as Parkinson's Disease Therapeutics
… target for the treatment of Parkinson’s disease. … Dyskinesia … Clinical Trial … Texas … United States … MJFF …
-
Validation of Lysosomal Enzymes Assay in CSF - One-year Extension of the RRIA: CSF Lysosomal Hydrolases' Activity as Possible Marker of Parkinson's Disease
… achieve a timely and focused pharmacological treatment. … Dyskinesia … Clinical Trial … California … United States … …